Mark Ragosa's Stock Option Exercise and Sale

Mark Ragosa, an officer at Kiniksa Pharmaceuticals International, plc, has filed a Form 144 indicating the intent to sell 20,000 Class A ordinary shares acquired through the exercise of employee stock options. The options were exercised on October 28, 2025, and the shares are to be sold on the same date. The aggregate market value of the shares is approximately $820,000. The sale will be facilitated by Charles Schwab & Co., Inc. Additionally, Ragosa reported a prior sale of 18,889 shares on August 4, 2025, which generated gross proceeds of $621,259. The filing highlights the ongoing transactions involving Ragosa's holdings in the company.